B-North Unquoted SME lender with unique proposition

Hardman & Co

B-North is raising capital ahead of getting its banking licence (due spring 2020). It will then attack the huge, profitable and poorly-served SME lending market. B-North combines i) state-of-the-art technology (built from scratch to address customers’ needs), ii) offering the £20bn+ p.a. commercial broker market an unparalleled service and an innovative remuneration model, and iii) experienced bankers based in empowered regional hubs. It should be more efficient than its peers, and will use technology to be close to customers. The financial model assumes a market share of just 2.5% in 2027. Delivery of this sees a highly profitable, and valuable, business, in our view.

  • Near-term capital raises:  B-North is currently raising up to £2m through private subscriptions through the Growthfunders and Crowdcube platforms. It anticipates raising a further £20m (through Berenberg), conditional on the approval of the banking licence due in March 2020. Further raises are planned.
  • “Reality-check”:  We have reviewed the company assumptions and believe them to be ambitious but credible. We have considered the absolute performance and the level of lending that peers have achieved. Importantly, B-North has multiple options to address any volume shortfall – most at a modest cost.
  • Valuation:  Given the growth profile of the company and associated uncertainties, any valuation must be treated with extreme caution. We provide a range of approaches (p46-48) that, on average, indicate B-North’s value in 2027 could be treble the amount of equity raised. We also provide a range of sensitivities.
  • Risks:  Credit risk is key for any bank. B-North will establish independent credit functions, and its technology will bring it close to customers interfacing directly with its management information. It has multiple options to address any loan growth shortfall. The economic cycle is important. The model is yet to be tested.
  • Investment summary:  B-North is still at the pre-revenue stage. Its model should be low-cost and deliver a superior service to customers and intermediaries. It has a conservative credit culture and uses state-of-the-art technology, written from scratch, to originate, service and manage its business. Funding will be via the deep best-buy retail deposit comparison sites. The potential market is huge, profitable and under-served, and major incumbents have selectively become uncompetitive.

DOWNLOAD THE FULL REPORT

Share on:

Latest Company News

Geiger Counter NAV up 42.8%, Uranium spot price rises 22% in January

Uranium markets strengthened at the start of the year as rising spot prices, institutional physical purchases and supportive US nuclear policy developments combined to reinforce investor focus on supply security and long-term demand.

MONY Group reports record 2025 revenue and EBITDA

MONY Group PLC delivered record revenue of £446.3m and adjusted EBITDA of £145.1m in 2025, driven by growth in Money and Home Services and continued momentum in its SuperSaveClub membership base.

Johnson Matthey updates Honeywell deal timeline and financial terms

Johnson Matthey Plc and Honeywell have agreed to extend the completion timeline for the Catalyst Technologies transaction to July 2026 and amend the financial terms. The revised enterprise value is £1.325 billion.

JD Sports to launch £200m share buyback programme in FY27

JD Sports Fashion plc will return £200m to shareholders through a two-tranche share buyback programme in FY27. The first £100m tranche begins immediately and is expected to complete by 31 July 2026.

TomCo and Valkor form 50:50 Greenfield Joint Venture and raise £550,000

TomCo plc has renewed its collaboration with Valkor LLC, issuing new membership interests in Greenfield Energy, LLC to create a 50:50 joint ownership structure.

Cizzle Biotechnology nears CLIA accreditation for early lung cancer test

Cizzle Biotechnology reports that its North American licensing partner, Cizzle Bio Inc, is in the final stages of CLIA accreditation for the Company’s CIZ1B lung cancer biomarker test, with submission expected in Q2 2026.

    Search

    Search